Ironwood Pharmaceuticals shares rise 13.21% after-hours as 2026 revenue guidance exceeds consensus.

Ironwood Pharmaceuticals (IRWD) surged 13.21% in after-hours trading following the company’s announcement of significantly raised 2026 revenue guidance, projecting $450M–$475M versus a $319.47M consensus. The upward revision, driven by a strategic price cut on its flagship drug Linzess for irritable bowel syndrome, unlocked stronger-than-expected sales momentum and market share gains. Additionally, recent FDA approval of Linzess for pediatric functional constipation expanded the drug’s addressable market, further boosting long-term revenue prospects. Analysts highlighted the guidance beat and positive pricing strategy as key catalysts, aligning with the stock’s sharp post-earnings rally. The move reflects renewed investor confidence in Ironwood’s ability to navigate competitive pressures and capitalize on its gastrointestinal portfolio.